KEYNOTE-001 findings add support to pembrolizumab for advanced melanoma

A third of patients with advanced or metastatic melanoma will achieve an objective response to treatment with the programmed cell death protein inhibitor pembrolizumab, suggest KEYNOTE-001 findings, regardless of whether they have previously been treated with ipilimumab.
Source: MedWire News - Category: Consumer Health News Tags: Melanoma Source Type: news